Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement
- 3 August 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (5) , 496-500
Abstract
Background— Patients with prosthetic heart valves have a higher risk of developing valve thrombosis and arterial thromboembolism. Antithrombotic therapy in the early postoperative period after biological aortic valve replacement (BAVR) is controversial. The American College of Cardiology/American Heart Association and European Society of Cardiology guidelines recommend the use of warfarin for the first 3 months after BAVR, although the American College Chest Physician guidelines suggest that the recommendations are very weak and that the risk/benefit is unclear. This prospective study investigated the efficacy of postoperative warfarin compared with aspirin in patients after aortic valve replacement. Methods and Results— Patients undergoing BAVR between 2001 and 2002 received 2 antithrombotic therapies: 141 patients received warfarin for the first 3 months, and 108 patients received only aspirin. The major end points evaluated were the rate of cerebral ischemic events, bleeding, and survival. There were 3 and 5 postoperative cerebral ischemic events between 24 hours and 3 months for patients treated with aspirin and warfarin, respectively. After 3 months, the incidence of cerebral ischemic events did not differ between the 2 groups. The rate of major bleeding events, the stroke-free survival, and the overall survival rates were not statistically significant between the warfarin and aspirin groups. Conclusions— There seem to be no advantages in performing early anticoagulation therapy compared with a low-antiplatelet regimen with regard to early cerebral ischemic events, bleeding, and survival. Currently there is no evidence to support the fact that warfarin is more effective than aspirin.Keywords
This publication has 30 references indexed in Scilit:
- Medtronic intact porcine bioprosthesis: 10 years’ experienceThe Annals of Thoracic Surgery, 1998
- Modern management of prosthetic valve anticoagulation.Mayo Clinic Proceedings, 1998
- Clinical performance of biological and mechanical prosthesesThe Annals of Thoracic Surgery, 1995
- Aortic Bioprosthesis Without Early Anticoagulation-Risk of ThromboembolismThe Thoracic and Cardiovascular Surgeon, 1995
- High risk of thromboemboli early after bioprosthetic cardiac valve replacementJACC, 1995
- Risk of thromboembolism with the aortic Carpentier-Edwards bioprosthesisThe Annals of Thoracic Surgery, 1995
- Eleven years' experience with Carpentier-Edwards biological valves in relation to survival and complicationsEuropean Journal of Cardio-Thoracic Surgery, 1989
- Guidelines for Reporting Morbidity and Mortality after Cardiac Valvular OperationsThe Annals of Thoracic Surgery, 1988
- Performance of the lonescu-Shiley Pericardial Valve in the Aortic Position: 100 Months Clinical ExperienceThe Thoracic and Cardiovascular Surgeon, 1986
- Thromboembolism in Patients with Aortic Porcine BioprosthesesThe Annals of Thoracic Surgery, 1985